1. Home
  2. CYCC vs CNFR Comparison

CYCC vs CNFR Comparison

Compare CYCC & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • CNFR
  • Stock Information
  • Founded
  • CYCC 1992
  • CNFR 2009
  • Country
  • CYCC Malaysia
  • CNFR United States
  • Employees
  • CYCC N/A
  • CNFR N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • CNFR Property-Casualty Insurers
  • Sector
  • CYCC Health Care
  • CNFR Finance
  • Exchange
  • CYCC Nasdaq
  • CNFR Nasdaq
  • Market Cap
  • CYCC 7.8M
  • CNFR 9.4M
  • IPO Year
  • CYCC N/A
  • CNFR 2015
  • Fundamental
  • Price
  • CYCC $16.04
  • CNFR $0.90
  • Analyst Decision
  • CYCC
  • CNFR
  • Analyst Count
  • CYCC 0
  • CNFR 0
  • Target Price
  • CYCC N/A
  • CNFR N/A
  • AVG Volume (30 Days)
  • CYCC 5.3M
  • CNFR 6.7K
  • Earning Date
  • CYCC 08-13-2025
  • CNFR 08-12-2025
  • Dividend Yield
  • CYCC N/A
  • CNFR N/A
  • EPS Growth
  • CYCC N/A
  • CNFR N/A
  • EPS
  • CYCC N/A
  • CNFR 1.96
  • Revenue
  • CYCC $14,000.00
  • CNFR $64,021,000.00
  • Revenue This Year
  • CYCC $137.21
  • CNFR $25.91
  • Revenue Next Year
  • CYCC N/A
  • CNFR N/A
  • P/E Ratio
  • CYCC N/A
  • CNFR $0.46
  • Revenue Growth
  • CYCC N/A
  • CNFR N/A
  • 52 Week Low
  • CYCC $3.08
  • CNFR $0.42
  • 52 Week High
  • CYCC $597.60
  • CNFR $1.91
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 60.33
  • CNFR 64.66
  • Support Level
  • CYCC $10.05
  • CNFR $0.81
  • Resistance Level
  • CYCC $19.87
  • CNFR $0.96
  • Average True Range (ATR)
  • CYCC 3.57
  • CNFR 0.06
  • MACD
  • CYCC 1.99
  • CNFR 0.01
  • Stochastic Oscillator
  • CYCC 77.07
  • CNFR 70.26

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

About CNFR Conifer Holdings Inc.

Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.

Share on Social Networks: